FL12 FAP-alpha CAR-T

FL12 FAP-alpha CAR-T is an affinity-optimized chimeric antigen receptor (CAR) T-cell therapy targeting Fibroblast Activation Protein alpha (FAPα). Developed by Optieum Biotechnologies using their high-throughput scFv library "Eumbody System," the FL12 clone was selected for its moderate structural avidity, which helps mitigate trogocytosis (the stripping of antigens from target cells) and subsequent T-cell exhaustion. The CAR construct utilizes a second-generation architecture with CD28 costimulatory and CD3ζ signaling domains. FL12 is designed to concurrently target FAPα-expressing tumor cells and the immunosuppressive tumor microenvironment, specifically cancer-associated fibroblasts (CAFs). Preclinical data in glioblastoma models have demonstrated superior real-time killing, improved persistence, and significant tumor growth suppression compared to conventional high-affinity FAP-targeted CAR-T cells.

Other names

FL12 FAPα CAR-T